Premium
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time
Author(s) -
Medved Milica,
Karczmar Greg,
Yang Cheng,
Dignam James,
Gajewski Thomas F.,
Kindler Hedy,
Vokes Everett,
MacEneany Peter,
Mitchell Myrosia T.,
Stadler Walter M.
Publication year - 2004
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.20061
Subject(s) - medicine , dynamic contrast , liver tissue , contrast (vision) , magnetic resonance imaging , dynamic contrast enhanced mri , nuclear medicine , time to peak , area under the curve , cancer , radiology , pathology , artificial intelligence , computer science
Purpose To evaluate variability of a simplified method for measuring semiquantitative DCE‐MRI parameters in patients with cancer and to explore effects of treatment with a putative anti‐angiogenic compound. Materials and Methods A total of 19 patients enrolled on treatment trials with the putative anti‐angiogenic agent SU5416 underwent contrast enhanced examinations, and 11 had a second examination eight weeks post therapy. Contrast media concentration as a function of time was calculated using changes in signal and literature baseline T 1 values in normal muscle or liver reference tissue. Semiquantitative DCE‐MRI parameters, including the area under the contrast concentration vs. time curve (AUC), were calculated for regions‐of‐interest in normal liver and muscle, and in tumors. Results The coefficients of variation for pretherapy parameters in normal tissue were 11% to 37%. No significant changes were detected in normal liver over two months of therapy. In tumors and muscle, a significant decrease in the AUC and maximum contrast concentration was observed. Conclusion Variability of semiquantitative DCE‐MRI parameters utilizing a method based on known T 1 values in a reference tissue is low enough to detect changes in tumors during therapy. Use of this method as a pharmacodynamic marker should be further investigated. J. Magn. Reson. Imaging 2004;20:122–128. © 2004 Wiley‐Liss, Inc.